| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 13.2 | 22.1 | 18.2 |
| Other income | 0.6 | 0.3 | 0.4 |
| Total income | 13.8 | 22.4 | 18.6 |
| Profit before exceptional items & tax | 1.2 | 3.7 | 2.7 |
| Profit before tax | 1.2 | 3.7 | 2.7 |
| Net profit | 0.5 | 2.8 | 2.2 |
| Operating margin | 8.7% | 16.5% | 14.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -77.30% |
|---|---|
| Net profit, quarter on quarter | -82.10% |
| Revenue, year on year | -27.50% |
BSE results filing, NSE: SANJIVIN. Figures extracted from the filing.
Sanjivani Paranteral Ltd: key numbers
- Share price
- ₹169.05
- Market cap
- ₹207.7 Cr
- Revenue (annual)
- ₹68.67 Cr
- Net profit (annual)
- ₹6.79 Cr
- P/E (TTM)
- 19.7×Sector 50.4×
- Promoter holding
- 31.56%+0.30% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sanjivani Paranteral Ltd
All →Sanjivani Paranteral Fund Raise
Sanjivani Paranteral clarified the objects of its proposed 5 lakh convertible warrant issue to BSE. Proceeds of ~₹5.80 Cr will fund capex and subsidiary working capital for expansion.
Sanjivani Paranteral Annual General Meeting
Sanjivani Paranteral Limited held its 32nd Annual General Meeting on September 16, 2026. The meeting concluded with resolutions on financial statements and director re-appointment.
Sanjivani Paranteral Investor Presentation: Key Takeaways
Sanjivani Paranteral Q1 FY27 consolidated revenue grew 33.8% YoY to ₹238.4 Mn, driven by the new Pune IV-fluid plant ramp-up. Transitioning to a multi-vertical platform with injectables, orals, and nutraceuticals.
- Call
- Guides 110% growth
Sanjivani Paranteral Q1 FY27 Results: Net Profit ₹2.5 Cr, Up 47.1% YoY
Sanjivani Paranteral Ltd reported revenue from operations of ₹23.8 Cr (+33.0% YoY) and net profit of ₹2.5 Cr (+47.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹2.5 Cr · +47.1% YoY
Sanjivani Paranteral Earnings Call: Key Takeaways
Sanjivani Paranteral Q4 FY26 earnings transcript. Management transitions to a multi-vertical platform with base formulation business and new IVF and nutraceutical ventures.
Sanjivani Paranteral Earnings Call: Key Takeaways
Sanjivani Paranteral's Q4 & FY26 presentation shows significant decline in standalone financials. Focus remains on injectables (53.5% FY26 revenue) and export markets (78.5% FY26 revenue).